Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, s...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Investing in Anti-HIV: How Anti-HIV Therapeutic Developers Can Reshape the Future of HIV Control
Despite decades of progress transforming HIV from a fatal diagnosis into a manageable chronic condition, today’s antiretroviral therapies still face a stubborn barrier: They work brilliantly in theory but fall short when access, adherence, and real-world challenges get in the way.
-
Formulation Strategies, Tech Advances, Challenges and Considerations in Novel Drug Delivery
The transformative impact of complex biopharmaceuticals hinges on integrating advanced delivery systems, often accelerated by AI modeling, with robust manufacturing practices and regulatory alignment to ensure stability, safety, and effective patient access.
-
Regulatory strategy reimagined: Three trends accelerating drug development
The regulatory landscape is being rewritten. The future belongs to those who anticipate, adapt and act with purpose. In this article we look at 3 macro trends that are redefining regulatory strategy.
-
Harmonising global approaches to transformative theranostics
This article explores the landscape, regulatory considerations, infrastructural and operational requirements along with future directions for expanding Radiopharmaceuticals and Theranostics therapies into clinical settings.
-
Multidrug-Resistant Infections Necessitate Bacteriophage Treatment: Can We Get There in Time?
As antibiotic resistance surges globally, bacteriophage therapy is emerging as a promising alternative for treating multidrug-resistant infections. To scale this life-saving approach, investment in phage development, clinical trials, and diagnostic infrastructure is urgently needed.
-
CRO reforms: Tilting scale towards accelerated growth and transparency
The article, featuring commentary from Nagalakshmi Shetty, highlights how India's clinical research sector is rapidly expanding. Regulatory reforms like the Central Drugs Standard Control Organisation's NDCR (Amendment) Rules 2024, mandatory CRO registration and digitised portals are boosting transparency, shortening approval timelines and positioning India as a global hub for clinical trials.
-
Keeping it real
In this PharmaTimes article, Nagalakshmi Shetty explores how clinical data science is evolving from traditional management toward intelligent, risk-based, patient-centric research frameworks.
-
Navigating, manufacturing, infrastructure and regulatory hurdles in CAR T-Cell therapy growth
Explore how industry leaders are overcoming manufacturing and regulatory hurdles to scale CAR-T cell therapies across Asia-Pacific.
-
ICON recognised as one of World's top companies for women
ICON have been included in Forbes' list of only 400 global companies. Based on a survey of approximately 120,000 women in more than 36 countries, positions were awarded to companies that have been identified as top performers in promoting gender equality and supporting women in the workplace.
-
Precision medicine meets machine learning: AI and oncology biomarkers
AI is redefining oncology biomarker discovery, unlocking new precision in patient selection and trial design. Explore how this evolving technology is shaping the future of cancer drug development.
